Mayer L E, Walsh B T
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
J Clin Psychiatry. 1998;59 Suppl 15:28-34.
The introduction of selective serotonin reuptake inhibitors (SSRIs), which are, in general, safer and more easily tolerated than conventional antidepressants, has had a profound effect on the treatment of affective illnesses and obsessive-compulsive disorder (OCD). A number of symptoms associated with eating disorders overlap those of depression and OCD, suggesting a theoretical and practical case for evaluating the SSRIs in the treatment of anorexia nervosa, bulimia nervosa, binge-eating disorder, and obesity. Despite the expectations for SSRIs in the treatment of eating disorders, clinical investigations have yielded mixed results. In this paper, results from clinical studies of SSRIs (with and without concomitant psychotherapy) in the treatment of anorexia and bulimia nervosa, binge eating disorder, and obesity are reviewed, directions for future research are suggested, and practical recommendations for the clinician are provided.
选择性5-羟色胺再摄取抑制剂（SSRI）的问世，总体而言，它比传统抗抑郁药更安全且耐受性更好，这对情感性疾病和强迫症（OCD）的治疗产生了深远影响。一些与饮食失调相关的症状与抑郁症和强迫症的症状重叠，这为评估SSRI在神经性厌食症、神经性贪食症、暴饮暴食症和肥胖症治疗中的作用提供了理论和实践依据。尽管人们对SSRI治疗饮食失调抱有期望，但临床研究结果却喜忧参半。本文回顾了SSRI（联合或不联合心理治疗）治疗神经性厌食症、神经性贪食症、暴饮暴食症和肥胖症的临床研究结果，提出了未来研究方向，并为临床医生提供了实用建议。
